MRSA skin infections and cellulitis-mimickers — the AU general practice guide

Community-associated MRSA is no longer an inpatient curiosity in Australia — it is a routine general-practice problem. The Australian Group on Antimicrobial Resistance (AGAR) 2023 surveillance data show that community-associated methicillin-resistant Staphylococcus aureus accounts for approximately 20–25% of Staphylococcus aureus skin and soft-tissue infections nationally, rising to over 50% in some Aboriginal and Torres Strait Islander communities of Central and Northern Australia, where the Panton–Valentine leukocidin (PVL)-positive ST93 strain is endemic. The PVL toxin drives the recurrent furunculosis, household clustering, and tissue-destructive abscesses that distinguish CA-MRSA from methicillin-susceptible Staphylococcus aureus (MSSA). Patients often describe a “spider bite” — this presentation is CA-MRSA until proven otherwise. At the same time, the field is complicated by the opposite problem: 30–75% of lower-limb diagnoses labelled cellulitis are wrong, with most actually being stasis dermatitis, contact dermatitis, lipodermatosclerosis, or DVT.

A. Core clinical — the AU general-practice framework

Classification and microbiology

• CA-MRSA — isolated within 48 hours of hospital presentation in a patient without recent healthcare contact. Typically SCCmec type IV or V, PVL-positive, and susceptible to clindamycin, TMP-SMX, and doxycycline.
• HA-MRSA — nosocomial; SCCmec type II or III, PVL-negative, multi-drug resistant. The dominant HA-MRSA clone in eastern Australia is ST22 (EMRSA-15); management requires vancomycin or linezolid.
• ST93 (“Queensland clone”) — dominant CA-MRSA in Australian community and ATSI settings; aggressive skin infection phenotype; susceptible to non-beta-lactam oral agents.

SSTI spectrum: furuncle → carbuncle → abscess → cellulitis → necrotising fasciitis. CA-MRSA disproportionately causes purulent, abscess-pattern SSTI; MSSA is more commonly implicated in non-purulent, spreading cellulitis.

Who is at risk for CA-MRSA

High-risk groups per eTG and AGAR surveillance data:

• Aboriginal and Torres Strait Islander communities, particularly in Central and Northern Australia
• Prior MRSA colonisation or household contact with a known MRSA case
• Contact sports: rugby, wrestling, AFL (shared equipment, skin-to-skin contact)
• Intravenous drug use
• Men who have sex with men
• Correctional facilities
• Military personnel
• Childcare workers
• Refugees from MRSA-endemic regions
• Recurrent skin abscesses (≥2 in 12 months)

History

• Presentation pattern — pain, warmth, swelling, ± fluctuance; the “spider bite” story (no actual bite seen, rapidly enlarging, central pustule or black eschar)
• Trajectory — hours vs days; CA-MRSA abscesses often enlarge rapidly over 24–48 hours
• Systemic features — fever, rigors, myalgia (sepsis; also toxic shock syndrome)
• Household contacts — similar lesions in household members? (clustering = decolonisation indication)
• High-risk exposures — sports, IVDU, recent hospitalisation, ATSI community context
• Prior MRSA — prior colonisation, prior abscess requiring I&D

Examination — distinguishing purulent from non-purulent SSTI

Feature	Favours CA-MRSA abscess	Favours MSSA non-purulent cellulitis
Fluctuance or point of fluctuance	✔	✗
Purulent discharge or central pustule	✔	✗
“Spider bite” story	✔	✗
Well-demarcated expanding erythema without central fluctuance	✗	✔
Lymphadenopathy	Both	Both
Bilateral lower-limb distribution	Unusual (see mimickers)	Unusual (see mimickers)
Febrile, systemically unwell	More likely	Less common

Systemic features are red-flag indicators — fever, tachycardia, hypotension, altered mental state → consider sepsis → urgent review or transfer.

Must examine for necrotising fasciitis: pain disproportionate to appearance, woody induration, dusky skin, crepitus, dishwater discharge → surgical emergency → refer immediately, do not delay for imaging.

Management — the treatment ladder

Step 1: Incision and drainage (I&D) for any fluctuant abscess. This is the cornerstone of treatment. Mistry et al. Lancet Infectious Diseases 2017 and Daum et al. NEJM 2017 confirmed that I&D alone achieves clinical cure in the majority — but adjunctive antibiotics improve outcomes in higher-risk patients.

Step 2: Adjunctive antibiotics for high-risk patients. Per eTG:

Agent	Dose	Duration	Notes
TMP-SMX (cotrimoxazole)	160/800 mg twice daily	7 days	First-line post-I&D for CA-MRSA; NEJM 2017 NNT ~9
Doxycycline	100 mg twice daily	5–7 days	Good CA-MRSA activity; eTG preferred empirical option in ATSI settings
Clindamycin	450 mg four times daily	5–7 days	Check local resistance; inducible resistance possible in erythromycin-resistant isolates

For non-purulent cellulitis without MRSA risk factors: standard beta-lactam (flucloxacillin or cephalexin) per eTG — MSSA is the likely pathogen.

Step 3: Wound care, review at 48 hours. Packing the cavity after I&D is optional (no robust evidence for benefit); review in 48 hours to confirm improvement. If worsening, reassess for inadequate drainage or alternative diagnosis.

B. Evidence — cellulitis misdiagnosis

The cellulitis-mimicker problem is underappreciated. Levell et al. BJD 2011 documented that the majority of lower-limb diagnoses labelled “cellulitis” referred to a dermatology unit were wrong. Weng et al. JAMA Dermatology 2017 quantified misdiagnosis rates of 30–75% across multiple cohorts, with consequent unnecessary hospitalisations, antibiotic courses, and C. difficile infections.

Common mimickers of lower-limb cellulitis:

Mimicker	Distinguishing features	Management direction
Stasis dermatitis	Bilateral; brown haemosiderin pigmentation; eczematous; chronic course; no fever	Compression, emollients, topical corticosteroid
Contact dermatitis	Distribution maps onto allergen (stockings, compression, footwear, topical agent); itch predominant	Remove allergen; topical corticosteroid
Lipodermatosclerosis	Chronic woody induration in gaiter area; inverted champagne bottle; no acute inflammatory flare	Compression; refer dermatology
Deep vein thrombosis	Unilateral; linear distribution; leg swelling; Doppler ultrasound	Anticoagulation
Lymphoedema	Dorsal foot involvement; Stemmer’s sign positive; non-pitting in later stages	Compression; lymphoedema therapist
Gout	Uric acid history; podagra; joint swelling; urate crystals	NSAIDs/colchicine; urate lowering

The diagnostic rule: bilateral, non-febrile, chronic lower-limb redness in a patient with chronic venous changes — reassess before prescribing antibiotics. If a third antibiotic course is being contemplated, consult dermatology or arrange imaging.

C. Decolonisation — household approach for recurrent MRSA

Recurrence rates approach 30% within 12 months without decolonisation. Household clustering is common — untreated contacts remain a reservoir. Boyce 2007 established the combined regimen:

Protocol for recurrent furunculosis (≥2 abscesses in 6 months):

1. Chlorhexidine 4% body wash — apply daily, leave on for 2 minutes, rinse off; 5 consecutive days for all household members simultaneously
2. Intranasal mupirocin 2% ointment — apply twice daily to both anterior nares for 5 consecutive days; use a cotton tip or little finger
3. Linen and clothing — launder all towels, bed linen, and clothing on the highest temperature tolerated, on the first day of decolonisation
4. No sharing — razors, towels, sports gear, washcloths during and after decolonisation
5. Repeat if recurrence occurs within 6 months

Decolonisation does not guarantee clearance in all cases and is not a substitute for treatment of active lesions, but it significantly reduces the recurrence cycle.

D. Australian operations

eTG antimicrobial guidance — specific to AU epidemiology

Therapeutic Guidelines provides the authoritative AU empirical antibiotic selection framework for skin and soft-tissue infections, incorporating the AGAR surveillance data for local resistance rates. For uncomplicated furuncle or carbuncle: I&D is primary; antibiotics only if spreading cellulitis, systemic features, immunocompromise, or face or groin involvement. For confirmed or suspected CA-MRSA: TMP-SMX, doxycycline, or clindamycin (as above). For severe or necrotising infection: hospital admission, IV vancomycin plus meropenem plus clindamycin, surgical referral.

When to culture

Sending a swab from an abscess before I&D is recommended in:

• ATSI communities and known MRSA-high-prevalence settings
• Recurrent abscesses (≥2 in 12 months) — to guide decolonisation
• Any patient with systemic features
• Any patient with treatment failure after adequate I&D and antibiotic course
• Immunocompromised patients

Culture and sensitivity guides definitive therapy. Empirical CA-MRSA cover is started where clinically indicated without waiting for results.

Indications for hospital admission

• Systemic sepsis (qSOFA ≥2, haemodynamic instability, altered mental state)
• Facial abscess with risk of cavernous sinus thrombosis
• Orbital or periorbital cellulitis
• Suspected necrotising fasciitis
• Failure of outpatient antibiotics plus I&D
• Immunocompromised patient with spreading infection
• Unable to tolerate oral antibiotics

Transfer for suspected necrotising fasciitis without delay — do not wait for imaging. The LRINEC score ≥6 (Wong CCM 2004) is suggestive but not required for the decision to transfer.

NPS MedicineWise and antibiotic stewardship

NPS MedicineWise endorses targeted antibiotic prescribing — using the narrowest effective agent based on likely pathogen and local resistance. Empirical broad-spectrum antibiotics (amoxicillin-clavulanate, cephalosporins) for uncomplicated MRSA-SSTI without confirmed pathogen are not recommended. I&D plus targeted anti-MRSA coverage outperforms broad-spectrum agents for CA-MRSA.

E. Special populations

Aboriginal and Torres Strait Islander patients, particularly in remote and Central Australia. CA-MRSA prevalence exceeds 50% in some communities. Household crowding, skin barrier disruption from scabies or impetigo, and water-supply limitations drive the epidemic. Treatment of impetigo and scabies (the entry-point infections) is part of the MRSA-control approach. Doxycycline is preferred as a single agent in eTG for these settings given favourable CA-MRSA susceptibility. Household decolonisation is particularly important in community-clustering contexts.

Children. CA-MRSA causes a high proportion of paediatric skin abscesses. I&D is safe in children; local anaesthetic infiltration around (not into) the abscess. Doxycycline is generally avoided in children under 8 years (dental staining) — TMP-SMX or clindamycin are the paediatric options per eTG.

Intravenous drug users. Higher-risk for HA-MRSA and bacteraemia in addition to CA-MRSA. Bacteraemia from IVDU-associated SSTI can seed endocarditis, bone, and joint infections. Blood cultures and echocardiography are warranted in this population with fever, positive blood cultures, or severe sepsis. Harm reduction counselling, clean needle access, and addiction medicine referral are part of the clinical response.

Immunocompromised patients. Lower threshold for IV antibiotics, blood cultures, and hospital admission. CA-MRSA in immunocompromised hosts carries risk of invasive disease — bone and joint infection, pneumonia, bacteraemia, septic arthritis.

When to escalate

Refer to emergency department or hospital same day when:

• Suspected necrotising fasciitis — pain disproportionate to appearance, woody induration, dusky skin, dishwater discharge, rapid progression
• Systemic sepsis — tachycardia, hypotension, fever with rigors, altered mental state
• Facial, orbital, or periorbital infection
• Treatment failure after 48–72 hours of adequate I&D plus oral antibiotics
• Immunocompromised patient with spreading infection or systemic features

Refer to dermatology when:

• Diagnosis in doubt after adequate initial assessment and treatment
• Recurrent SSTI not responding to decolonisation
• Suspected atypical or inflammatory mimicker (pyoderma gangrenosum, vasculitis, drug eruption)

What this article is and is not

This is general health information drawn from Therapeutic Guidelines (eTG), AGAR surveillance 2023, Australian Medicines Handbook, NPS MedicineWise, and the peer-reviewed SSTI literature including the Mistry Lancet ID and Daum NEJM 2017 trials. It is not personal medical advice and does not create a doctor–patient relationship. Antibiotic choices should always be confirmed against current local resistance patterns and eTG.

For after-hours advice: healthdirect 1800 022 222. For wound care information: HealthDirect — Skin infections, Better Health Channel.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Antibiotic: skin and soft tissue infection
2. AGAR — Australian Group on Antimicrobial Resistance: Staphylococcus aureus Surveillance 2023
3. Tong SYC et al. — Community-associated MRSA in Australia. CID 2014
4. Mistry RD et al. — TMP-SMX vs placebo after I&D for skin abscess. Lancet Infectious Diseases 2017
5. Daum RS et al. — TMP-SMX vs clindamycin vs placebo after I&D. NEJM 2017
6. Wong CH et al. — LRINEC score for necrotising fasciitis. Crit Care Med 2004
7. Levell NJ et al. — Cellulitis: a dermatological perspective. BJD 2011
8. Weng QY et al. — Costs and consequences of misdiagnosed lower extremity cellulitis. JAMA Dermatol 2017
9. Boyce JM — MRSA decolonisation: chlorhexidine and mupirocin. Infect Control Hosp Epidemiol 2007
10. Australian Medicines Handbook (AMH)
11. NPS MedicineWise
12. HealthDirect — Skin infections
13. Better Health Channel